Discoveries from ARVO
Discoveries from ARVO
Source/Disclosures
Source:

Martel J. Optogenetics in the Clinic: PIONEER, a Phase 1/2a Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa. Presented at: Association for Research in Vision and Ophthalmology annual meeting; May 6, 2020 (virtual meeting).

Disclosures: Martel reports no relevant financial disclosures.
July 06, 2020
2 min read
Save

Gene therapy, light stimulation combination tolerated, safe in retinitis pigmentosa

Source/Disclosures
Source:

Martel J. Optogenetics in the Clinic: PIONEER, a Phase 1/2a Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa. Presented at: Association for Research in Vision and Ophthalmology annual meeting; May 6, 2020 (virtual meeting).

Disclosures: Martel reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A combination of optogenetic gene therapy and use of a light stimulation medical device for the treatment of retinitis pigmentosa was well tolerated among the first cohort of patients enrolled in the PIONEER study, according to data reported at the Association for Research in Vision and Ophthalmology annual meeting.

According to the abstract, there are more than 100 known mutations of retinitis pigmentosa (RP).

Joseph Martel MD
Joseph N. Martel

“It’s a unique trial and a unique approach for vision restoration that is independent of the underlying gene defect,” Joseph N. Martel, MD, assistant professor of ophthalmology at the University of Pittsburgh School of Medicine, told Healio. “So, as a result, it has broad applicability among many different causes of RP and also perhaps broader applicability to other retinal degeneration that causes severe loss of vision.”

The phase 1/2a open-label PIONEER study evaluated the tolerability and safety of the optogenetic treatment GS030 among patients with non-syndromic RP.

The study included three dose-escalation cohorts – 5E10, 1.5E11, 5E11 vg/eye, – with each consisting of three patients.

“Right now, we are escalating the dose to find the best tolerated but highest dose,” Martel said.

In the first cohort, the researchers reported no serious adverse events or study discontinuations up to 1 year after treatment administration. Mild anterior chamber inflammation responsive to corticosteroid treatment and mild sensitivity to light starting after drug product administration but before light stimulation by the goggles were the most commonly reported adverse events. Two months after patients received the gene therapy, the light stimulating medical device was used to stimulate ChR-tdT.

In the second cohort, which is ongoing, two patients received 1.5E11 vg/eye, and no serious or unexpected adverse events were reported.

Treatment with the highest dose will occur during the third cohort, which the researchers said is planned for some time in Q1 of 2020.

The therapy is minimally invasive, as it is delivered via an intravitreal injection instead of surgery, and it is not an ongoing therapy, occurring only one time.

“The therapy itself is a gene that was isolated from green algae. Its channelrhodopsin (ChR-tdT), which is a light sensitive protein. The target cell is an inter retinal cell called retinal ganglion cell, and retinal ganglion cells normally are not light sensitive cells in the retina,” Martel explained. “But the objective of this therapy is to transform these retinal ganglion cells to confer some light sensitivity so that they behave like the photo receptors that are lost in patients with RP.”